Effects of lycopene and apigenin on human umbilical vein endothelial cells in vitro under angiogenic stimulation

Acta Histochemica

Volumn 114, Issue 2, 2012, Pages 94-100

  Şahin, Mehmet ^a   Şahin, Emel ^a   Gümüşlü, Saadet ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Angiogenesis; Apigenin; Cancer; HUVEC; Lycopene

Indexed keywords

APIGENIN; LYCOPENE;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; TREATMENT INDICATION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANTICARCINOGENIC AGENTS; APIGENIN; CAROTENOIDS; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CELL PROLIFERATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS;

EID: 84856451575     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2011.03.004     Document Type: Article

References (25)

1. Agarwal S., Rao A.V. Tomato lycopene and its role in human health and chronic diseases. CMAJ 2000, 163:739-744.
2. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404-407.
3. Erdogan A., Most A.K., Wienecke B., Fehsecke A., Leckband C., Voss R., et al. Apigenin-induced nitric oxide production involves calcium-activated potassium channels and is responsible for antiangiogenic effects. J Thromb Haemost 2007, 5:1774-1781.
4. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971, 133:275-288.
5. Gann P.H., Ma J., Giovannucci E., Willett W., Sacks F.M., Hennekens C.H., et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999, 59:1225-1230.
6. Giovannucci E., Rimm E.B., Liu Y., Stampfer M.J., Willett W.C. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002, 94:391-398.
7. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
8. Hantz H.L., Young L.F., Martin K.R. Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med (Maywood) 2005, 230:171-179.
9. Huang C.S., Shih M.K., Chuang C.H., Hu M.L. Lycopene inhibits cell migration and invasion and upregulates Nm23-H1 in a highly invasive hepatocarcinoma, SK-Hep-1 cells. J Nutr 2005, 135:2119-2123.
10. Hwang E.S., Lee H.J. Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK-Hep1 human hepatoma cells. Exp Biol Med (Maywood) 2006, 231:322-327.
11. Ivanov N.I., Cowell S.P., Brown P., Rennie P.S., Guns E.S., Cox M.E. Lycopene differentially induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell lines. Clin Nutr 2007, 26:252-263.
12. Karas M., Amir H., Fishman D., Danilenko M., Segal S., Nahum A., et al. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 2000, 36:101-111.
13. Kim H.P., Mani I., Iversen L., Ziboh V.A. Effects of naturally occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. Prostaglandins Leukot Essent Fatty Acids 1998, 58:17-24.
14. Kim M.H. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J Cell Biochem 2003, 89:529-538.
15. Lin C.Y., Huang C.S., Hu M.L. The use of fetal bovine serum as delivery vehicle to improve the uptake and stability of lycopene in cell culture studies. Br J Nutr 2007, 98:226-232.
16. Livny O., Kaplan I., Reifen R., Polak-Charcon S., Madar Z., Schwartz B. Lycopene inhibits proliferation and enhances gap-junction communication of KB-1 human oral tumor cells. J Nutr 2002, 132:3754-3759.
17. Martin K.R., Wu D., Meydani M. The effect of carotenoids on the expression of cell surface adhesion molecules and binding of monocytes to human aortic endothelial cells. Atherosclerosis 2000, 150:265-274.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
19. Park Y.O., Hwang E.S., Moon T.W. The effect of lycopene on cell growth and oxidative DNA damage of Hep3B human hepatoma cells. Biofactors 2005, 23:129-139.
20. Prakash P., Russell R.M., Krinsky N.I. In vitro inhibition of proliferation of estrogen-dependent and estrogen-independent human breast cancer cells treated with carotenoids or retinoids. J Nutr 2001, 131:1574-1580.
21. Sahin M., Sahin E., Gumuslu S. Cyclooxygenase-2 in cancer and angiogenesis. Angiology 2009, 60:242-253.
22. Salman H., Bergman M., Djaldetti M., Bessler H. Lycopene affects proliferation and apoptosis of four malignant cell lines. Biomed Pharmacother 2007, 61:366-369.
23. Schleef R.R., Birdwell C.R. The effect of fibrin on endothelial cell migration in vitro. Tissue Cell 1982, 14:629-636.
24. Tosetti F., Ferrari N., De Flora S., Albini A. 'Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. Faseb J 2002, 16:2-14.
25. Trochon V., Blot E., Cymbalista F., Engelmann C., Tang R.P., Thomaidis A., et al. Apigenin inhibits endothelial-cell proliferation in G(2)/M phase whereas it stimulates smooth-muscle cells by inhibiting P21 and P27 expression. Int J Cancer 2000, 85:691-696.